Sindan, up 47% in 2003

Pharmaceutical company Sindan, specialising in production and distribution of cancer drugs, concluded 2003 with about $60 million turnover, up 47% from the previous year, its representatives say. The turnover was derived from both the production and sale of drugs and from the operations of the distribution arm of the group, which sells drugs made by other companies, as well. “The export and broadening of our distribution operations were the drives behind our growth in 2003. We consolidated our position on the Central European markets (Poland and Czech Republic) and plan to start exporting to Russia in the first half in 2004,” Aurel Tudose, Sindan’s general manager said. Exports were one of the main strategic concerns for Sindan over the last few years. The company makes and distributes cancer drugs only, therefore its growth potential on the domestic market is 100% up to the funds allocated by the Romanian State for cancer treatment. ZF